178 related articles for article (PubMed ID: 37936709)
1. How immune breakthroughs could slow disease progression and improve prognosis in COVID-19 patients: a retrospective study.
Wang Y; Zhao B; Zhang X; Zhang X; Gao F; Yuan X; Ren X; Li M; Liu D
Front Immunol; 2023; 14():1246751. PubMed ID: 37936709
[TBL] [Abstract][Full Text] [Related]
2. Immune cell profiling and antibody responses in patients with COVID-19.
Rezaei M; Mahmoudi S; Mortaz E; Marjani M
BMC Infect Dis; 2021 Jul; 21(1):646. PubMed ID: 34225645
[TBL] [Abstract][Full Text] [Related]
3. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
4. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
[TBL] [Abstract][Full Text] [Related]
5. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
6. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
7. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
8. The dynamics of immune response in COVID-19 patients with different illness severity.
Zhang B; Yue D; Wang Y; Wang F; Wu S; Hou H
J Med Virol; 2021 Feb; 93(2):1070-1077. PubMed ID: 32910461
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination.
Xu J; Zheng J; Tan Y; Cai J; Xiang Y; Ling H; Li Z; Bai Q
Viral Immunol; 2023; 36(6):389-400. PubMed ID: 37276049
[TBL] [Abstract][Full Text] [Related]
10. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus.
Liu D; Lan L; Luo D; Zhao B; Wei G; He Y; Zhang R; Liu Y
Diabetes Res Clin Pract; 2020 Sep; 167():108341. PubMed ID: 32707212
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients.
Tajuelo A; Carretero O; García-Ríos E; López-Siles M; Cano O; Vázquez M; Más V; Rodríguez-Goncer I; Lalueza A; López-Medrano F; Juan RS; Fernández-Ruiz M; Aguado JM; McConnell MJ; Pérez-Romero P
Front Immunol; 2022; 13():878812. PubMed ID: 35547738
[TBL] [Abstract][Full Text] [Related]
14. Persistence of T-Cell Immunity Responses against SARS-CoV-2 for over 12 Months Post COVID-19 Infection in Unvaccinated Individuals with No Detectable IgG Antibodies.
Pitiriga VC; Papamentzelopoulou M; Konstantinakou KE; Vasileiou IV; Sakellariou KS; Spyrou NI; Tsakris A
Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140169
[TBL] [Abstract][Full Text] [Related]
15. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021.
Edelstein M; Wiegler Beiruti K; Ben-Amram H; Bar-Zeev N; Sussan C; Asulin H; Strauss D; Bathish Y; Zarka S; Abu Jabal K
Clin Infect Dis; 2022 Aug; 75(1):e572-e578. PubMed ID: 35279028
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.
Chensue SW; Siler AF; Kim PS; Dimcheff DE; Daghfal DJ; Prostko J; Frias E; Linder KA; Schildhouse RJ
Microbiol Spectr; 2022 Dec; 10(6):e0274722. PubMed ID: 36409132
[TBL] [Abstract][Full Text] [Related]
18. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern.
Ruhl L; Kühne JF; Beushausen K; Keil J; Christoph S; Sauer J; Falk CS
Front Immunol; 2023; 14():1120010. PubMed ID: 37033958
[TBL] [Abstract][Full Text] [Related]
19. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
20. Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs.
Maurya R; Shamim U; Mishra P; Swaminathan A; Raina A; Tarai B; Budhiraja S; Pandey R
Microbiol Spectr; 2023 Jun; 11(3):e0429222. PubMed ID: 37022180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
